WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has unveiled groundbreaking results from the CLEAR study, the first head-to-head randomized controlled trial comparing the UroLift™ System with Rezūm™ ...

WAYNE, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced ...

UroLift is a minimally invasive treatment option for benign prostatic hyperplasia (BPH), also called enlarged prostate. Medicare covers the UroLift procedure when a doctor deems it medically necessary ...

Men with lower urinary tract symptoms linked to an enlarged prostate report better outcomes from a surgical implant than with a commonly prescribed drug for the condition, according to new data ...

WAYNE, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX) (NYSE: TFX), a leading global provider of medical technologies, today announced the launch of a new national advertising ...

Presentations at the 37th Annual European Association of Urology Congress to Demonstrate Measurable and Sustained Improvement of BPH Symptoms and IPSS Scores WAYNE, Pa., July 01, 2022 (GLOBE NEWSWIRE) ...

Rates of surgical retreatment, alongside patient experience factors such as complications and adverse events (AEs), are important considerations when patients and their providers assess BPH therapies.